Novartis ranked second in the 2021 Access to Medicine Index (ATMIndex), maintaining the same leading position as in 2018, in recognition of its long-standing efforts to improve worldwide access to healthcare. Novartis performed strongly across all three technical areas and was the industry leader in product delivery, being highlighted as the only company that applies equitable access strategies in low-income countries for all its products assessed in this category.
The Index measures the performance of the top-20 pharmaceutical companies to improve access to medicines and healthcare in developing countries. It focuses on three technical areas: governance of access; research and development (R&D); and product delivery.
In the governance category, we achieved second place for embedding access to medicines in our corporate strategy through the Novartis access principles and having access-related incentives for our CEO and senior executives. Novartis ranked third in the R&D category and was recognized as the only company that both commits to post-trial access to all clinical trial participants and considers post-trial affordability in countries in scope.